Latest articles from Cancer Therapy Advisor News
Phase 1 trials of investigational drug candidates in oncology are increasing, likely as a way of involving more patients with rare tumors. from Latest articles from Cancer Therapy Advisor News https://ift.tt/2SuXXmS
While BIA-ALCL had previously only been associated with breast implants, this case provides evidence for a possible case of gluteal implant-associated ALCL. from Latest articles from Cancer Therapy Advisor News https://ift.tt/2…
The approval was supported by data from the phase 3, multicenter, randomized, double-blind, placebo-controlled EORTC1325/KEYNOTE-054 trial (N=1019) which included patients with completely resected stage IIIA (>1mm lymph node m…
The approval was based on data from the phase 3 TAGS trial (N=507) which evaluated Lonsurf plus best supportive care (BSC) vs placebo plus BSC in patients with advanced gastric cancer. from Latest articles from Cancer Therapy A…
Researchers identify a number of patient-, disease-, and treatment-related differences between Hispanic and non-Hispanic patients diagnosed with gastric cancer. from Latest articles from Cancer Therapy Advisor News https://ift.…
The proportion of seminal oncology research articles authored by women that are cited in the NCCN guidelines is reflected in the proportion of female members on guideline panels. from Latest articles from Cancer Therapy Advisor…
Detection of a specific germline alteration in HSD3B1 may help oncologists gauge the potential benefit of upfront abiraterone or ADT in Japanese patients with prostate cancer. from Latest articles from Cancer Therapy Advisor Ne…
Patients with advanced, pretreated HCC receiving pembrolizumab in a phase 3 trial did not experience OS or PFS benefits compared with those receiving placebo. from Latest articles from Cancer Therapy Advisor News https://ift.tt…
The phase 3 CAUREL trial evaluating the combination of an anti-PD-L1 and an EGFR-TKI in advanced EGFR-mutant NSCLC was terminated early because of safety concerns from a related trial. from Latest articles from Cancer Therapy A…
Testing should be made available to all patients with a family or personal history of breast cancer, according to the American Society of Breast Surgeons. from Latest articles from Cancer Therapy Advisor News https://ift.tt/2SP…
Clinical outcomes of patients with hypodiploid B-ALL are poor compared with those with B-ALL not characterized by hypodiploidy, according to researchers. from Latest articles from Cancer Therapy Advisor News https://ift.tt/2GxL…
High tumor expression of IDO1 may identify whether a patient is likely to respond to immunotherapy, according to study authors. from Latest articles from Cancer Therapy Advisor News http://bit.ly/2Ng7MUS
Researchers examined low-level estimates of ambient benzene to investigate whether it was associated with increased cancer incidence across a nationwide cohort. from Latest articles from Cancer Therapy Advisor News http://bit.l…
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported. from Latest articles from Cancer Therapy Advisor News http://bit.ly/2NbO3Wm
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab. from Latest articles from Cancer Therapy Advisor News http://bit.ly/2STUcM5
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status. from Latest articles from Cancer Ther…
New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus. from Latest articles from Cancer Therapy Advisor News http://bit.ly/2SSRLcK
Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone. from Latest articles from Cancer Therapy Advisor News h…
Postoperative radiation therapy with adjuvant chemotherapy prolonged disease-free survival and overall survival in patients with locally advanced urothelial carcinoma. from Latest articles from Cancer Therapy Advisor News http:…
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib. from Latest articles from Cancer Therapy Ad…
